Ventures

The Venous Stent is a new type of stent designed to help with conditions like deep vein thrombosis (DVT) and post-thrombotic syndrome (PTS). Unlike older stents, this one can adjust in length and has multiple parts, making it more flexible and better for the veins. It helps improve blood flow and healing in the veins, potentially reducing the need for long-term medication.

Amotio addresses the challenge of revision surgeries for hip, knee, and shoulder implants with their innovative approach. Collaborating with expert revision surgeons and guided by NLC, they offer a patented solution for improved implant revision surgery. By developing unique bone cement removal devices and integrating advanced patient-specific 3D surgical planning and printing technology, Amotio aims to set a new standard for excellence in these surgeries. Their goal is to reduce complexity, trauma, and recovery time while cutting costs for healthcare providers.

Rare diseases often lead to years of diagnostic odyssey and immense patient suffering. Therefore Genorare is set to dramatically shorten this diagnostic journey for individuals with rare diseases. Genorare's platform enables real-time, secure analysis of genomic, clinical, and phenotypic data using Large Language Models, predictive analytics, and Fully Homomorphic Encryption. A key innovation is the use of Fully Homomorphic Encryption, a next-generation privacy technology that allows for advanced analysis while ensuring patient data remains completely secure, promising a new standard of care for the rare disease community.

Exolvo Biosciences, a collaboration between NLC Health Ventures and Verily (Google) Life Sciences, is revolutionizing oral drug delivery for large molecules like biologics. Our smart capsule technology, originating from the Google X moonshot program, eliminates painful injections and maximizes medication effectiveness. With ongoing pre-clinical testing and plans for an IND package in the U.S., we're poised to redefine drug delivery standards.

Neurolieve Biosciences, a pre-clinical stage company, is developing Fc2-13 GalR2, an innovative bioengineered protein (FC fusion protein) targeting neuropathic pain. Peripheral Neuropathy, a debilitating condition affecting millions, damages the peripheral nervous system, causing severe discomfort and lowering quality of life. The fusion protein reduces peripheral neuron excitability, providing pain relief. After successful in vitro and in vivo validations, the company is advancing towards GLP toxicology studies completion.

Hemeo addresses the challenge of treating ICU patients with coagulation issues by developing a decision support system. This system uses patient data and real-time monitoring to accurately assess bleeding and thrombosis risks. By modeling the coagulation system with a smart algorithm, it provides personalized recommendations to clinicians, helping them make more informed therapy decisions. With ICU patients at high risk for venous thromboembolism and bleeding incidents, this solution aims to improve patient outcomes and reduce uncertainty in treatment.

MLA Diagnostics improves melanoma diagnosis, offering personalized measurement of malignancy levels. Traditional diagnosis often leads to overtreatment or undertreatment, resulting in patient distress or undetected cancer progression. By analyzing methylation, our test provides accurate prognosis, enabling tailored treatment plans and saving lives. With the melanoma therapeutics market on the rise, our innovative solution is poised to make a significant impact, improve patient outcomes and create opportunities.

Sigilla Medical is developing an innovative, implant-free radiofrequency device designed to close PFOs (patent foramen ovale) in stroke-risk patients. PFOs are associated with cryptogenic stroke and migraine, and current treatment involves placing a large metal device that spans the septum of the heart in an otherwise young and healthy patient. Sigilla’s device offers a safer, more efficient alternative by using controlled radiofrequency to seal the PFO without the need for implants. This less-invasive approach reduces procedural risk and adverse cardiac events while leaving options open for future minimally invasive procedures.